Syndax Announces Participation in February Investor Conferences
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: PR Newswire
WALTHAM, Mass., Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:Guggenheim SMID Cap Biotech Conference in New York, NY with a fireside chat on Thursday, February 6, 2025, at 10:30 a.m. ETCiti's 2025 Virtual Oncology Leadership Summit with a fireside chat on Wednesday, February 19, 2025, at 9:00 a.m. ETA live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.About SyndaxSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib),
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharma: Continuing Execution In AML [Seeking Alpha]Seeking Alpha
- Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025GlobeNewswire
- Syndax Pharmaceuticals (NASDAQ:SNDX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $56.00 price target on the stock.MarketBeat
- Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment ContinuumGlobeNewswire
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
SNDX
Earnings
- 11/3/25 - Beat
SNDX
Sec Filings
- 12/19/25 - Form 8-K
- 12/1/25 - Form 4
- 11/3/25 - Form 10-Q
- SNDX's page on the SEC website